Colorectal cancer (CRC) is a heterogeneous disease at the cellular and molecular levels.
Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene in CRC, with mutations in …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

Background The phagocytosis checkpoints of CD47/SIRPα, PD1/PDL1, CD24/SIGLEC10,
and MHC/LILRB1 have shown inhibited phagocytosis of macrophages in distinct tumors …

Simple Summary Immune Checkpoint Inhibitors (ICIs) have demonstrated clinical efficacy in
Microsatellite Instability High Colorectal Cancer (MSI-H CRC). However, in Microsatellite …

RAS genes are the most frequently mutated oncogenes in cancer. These mutations occur in
roughly half of the patients with colorectal cancer (CRC). RAS mutant tumors are resistant to …

Simple Summary Late-stage colorectal cancer treatment often involves chemotherapy and
radiation that can cause dose-limiting toxicity, and therefore there is great interest in …

Background The immune response has important clinical value in colorectal cancer (CRC)
in both prognosis and response to immunotherapy. This study aims to explore tumour …

Aberrant tumor metabolism is a hallmark of cancer in which metabolic rewiring can support
tumor growth under nutrient deficient conditions. KRAS mutations occur in 35–45% of all …

Simple Summary Our group recently presented Stroma AReactive Invasion Front Areas
(SARIFA) as an independent prognostic biomarker for a poorer outcome in different …

Kirsten rats sarcoma viral oncogene (KRAS), the first discovered human oncogene, has long
been recognized as “undruggable”. KRAS mutations frequently occur in multiple human …